Thymosin Beta-4 During Pregnancy Accelerates Fetal Organ Development in Mice
Two doses of thymosin beta-4 during late pregnancy produced longer newborn mice with more advanced development of lungs, heart, kidneys, brain cortex, and notochord compared to untreated controls.
Quick Facts
What This Study Found
Maternal TB4 treatment (6 mg/kg on days E14 and E17) increased newborn cranio-caudal length and accelerated development of lungs, heart, kidneys, cerebral cortex, and notochord compared to control newborns.
Key Numbers
6 mice; TB4 6 mg/kg IP on E14 and E17; increased cranio-caudal length; advanced development of lungs, heart, kidney, cerebral cortex, notochord
How They Did This
Animal study. 6 pregnant mice received intraperitoneal TB4 injections (6 mg/kg in PBS) on gestational days E14 and E17. Newborns assessed for body length and organ development by histology.
Why This Research Matters
Preterm birth is a leading cause of infant mortality, largely because organs haven't finished developing. If TB4 can accelerate organ maturation, it could help premature babies survive with fewer complications.
The Bigger Picture
TB4 is already known for wound healing and tissue repair in adults. This study extends its potential to prenatal medicine, suggesting it could promote organ maturation in at-risk pregnancies — a novel application for this well-studied peptide.
What This Study Doesn't Tell Us
Very small animal study (6 pregnant mice). No functional assessments of organ maturity. Long-term effects on offspring not evaluated. Mouse development may not directly translate to human pregnancy.
Questions This Raises
- ?Could TB4 treatment help improve outcomes for premature human infants at risk of underdeveloped organs?
- ?What is the optimal timing and dosing window for TB4 during pregnancy?
- ?Does accelerated organ development from TB4 translate to better functional outcomes after birth?
Trust & Context
- Key Stat:
- 5 organs accelerated TB4 treatment during pregnancy advanced development of lungs, heart, kidneys, cerebral cortex, and notochord in newborn mice
- Evidence Grade:
- Low evidence grade: very small animal study (6 mice) with histological endpoints only. No functional assessments or long-term follow-up.
- Study Age:
- Published in 2021. TB4 research continues primarily in wound healing and regenerative medicine contexts.
- Original Title:
- Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.
- Published In:
- European review for medical and pharmacological sciences, 25(1), 431-437 (2021)
- Authors:
- Faa, G, Piras, M, Mancuso, L, Coni, P, Pichiri, G, Orrù, G, Fanni, D, Gerosa, C, Cao, G, Taibi, R, Pavone, P, Castagnola, M
- Database ID:
- RPEP-05370
Evidence Hierarchy
Frequently Asked Questions
What is thymosin beta-4?
TB4 is the most abundant beta-thymosin peptide in humans. It regulates cell structure (actin), promotes blood vessel growth, supports cell survival, and helps tissues heal. It is being studied for wound healing, cardiac repair, and now potentially fetal development.
Could this help premature babies?
Theoretically, if TB4 accelerates organ development, it could help prepare premature babies' organs before or shortly after early delivery. However, this has only been tested in mice and would require extensive safety and efficacy testing before any human application.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05370APA
Faa, G; Piras, M; Mancuso, L; Coni, P; Pichiri, G; Orrù, G; Fanni, D; Gerosa, C; Cao, G; Taibi, R; Pavone, P; Castagnola, M. (2021). Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.. European review for medical and pharmacological sciences, 25(1), 431-437. https://doi.org/10.26355/eurrev_202101_24411
MLA
Faa, G, et al. "Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.." European review for medical and pharmacological sciences, 2021. https://doi.org/10.26355/eurrev_202101_24411
RethinkPeptides
RethinkPeptides Research Database. "Thymosin beta-4 prenatal administration improves fetal devel..." RPEP-05370. Retrieved from https://rethinkpeptides.com/research/faa-2021-thymosin-beta4-prenatal-administration
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.